TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34658139

Group type: EXPERIMENTAL
Intervention: Silicone gel containing 5% onion extract
Number of subjects: 0

Group type: COMPARATOR
Intervention: Silicone gel containing vitamin C (Control)
Number of subjects: 0
Study: 34037282

Group type: EXPERIMENTAL
Intervention: palbociclib (125 mg/day, 3/1 schedule)–fulvestrant (500 mg, intramuscular injection)
Number of subjects: 521

Group type: COMPARATOR
Intervention: placebo-fulvestrant
Number of subjects: 521
Study: 36231171

Group type: EXPERIMENTAL
Intervention: Pain Education Therapy (PET) group (n = 24)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control Group (CG) (n = 26)
Number of subjects: 50
Study: 33627290

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided serratus plane block (SPB)
Number of subjects: 30
Study: 32340738

Group type: EXPERIMENTAL
Intervention: Cold application for 20 minutes
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Cold application for 30 minutes
Number of subjects: 105
Study: 35986170

Group type: COMPARATOR
Intervention: Traditional dysphagia therapy (TDT)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: TDT with neuromuscular electrical stimulation (NMES)
Number of subjects: 34
Study: 33722875

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA), initiated prehospital and continued in hospital over 8 hours
Number of subjects: 1316

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1316

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA)
Number of subjects: 1316
Study: 34056000

Group type: EXPERIMENTAL
Intervention: Carbon nanoparticle laparoscopic operation
Number of subjects: 180

Group type: COMPARATOR
Intervention: Traditional laparoscopic operation
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 180
Study: 33035202

Group type: EXPERIMENTAL
Intervention: Percutaneous transforaminal endoscopic decompression (PTED)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Fenestration
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: PTED
Number of subjects: 188
Study: 35253163

Group type: EXPERIMENTAL
Intervention: Pilates exercises plus conventional PT program
Number of subjects: 34

Group type: COMPARATOR
Intervention: Standard PT program
Number of subjects: 34
Study: 34022495

Group type: EXPERIMENTAL
Intervention: Insomnia
Number of subjects: 762

Group type: EXPERIMENTAL
Intervention: Cocaine use
Number of subjects: 762

Group type: EXPERIMENTAL
Intervention: Alcohol use
Number of subjects: 762

Group type: EXPERIMENTAL
Intervention: Physical aggression toward partners (PA-P)
Number of subjects: 762

Group type: EXPERIMENTAL
Intervention: Physical aggression toward non-partners (PA-NP)
Number of subjects: 762

Group type: EXPERIMENTAL
Intervention: Physical injury of partners (PI-P)
Number of subjects: 762

Group type: EXPERIMENTAL
Intervention: Physical injury of non-partners (PI-NP)
Number of subjects: 762

Group type: EXPERIMENTAL
Intervention: Insomnia moderating cocaine use and PA-NP
Number of subjects: 762

Group type: EXPERIMENTAL
Intervention: Insomnia and violence prediction
Number of subjects: 762
Study: 32155105

Group type: EXPERIMENTAL
Intervention: Chinese radiologists
Number of subjects: 424

Group type: EXPERIMENTAL
Intervention: U.S. radiologists
Number of subjects: 424

Group type: COMPARATOR
Intervention: COVID-19 pneumonia
Number of subjects: 424
Study: 36220625

Group type: EXPERIMENTAL
Intervention: SDM tool used in encounters
Number of subjects: 922

Group type: COMPARATOR
Intervention: Usual care encounters
Number of subjects: 922

Group type: EXPERIMENTAL
Intervention: SDM tool exposure
Number of subjects: 922
Study: 34259433

Group type: EXPERIMENTAL
Intervention: povidone iodine
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: hydrogen peroxide
Number of subjects: 32

Group type: COMPARATOR
Intervention: benzethonium chloride
Number of subjects: 32

Group type: COMPARATOR
Intervention: tap water
Number of subjects: 32
Study: 35922794

Group type: EXPERIMENTAL
Intervention: Liposomal Ginkgo biloba extract (Ginkgosome™)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Comparator formulation of Ginkgo biloba extract
Number of subjects: 13
Study: 33650630

Group type: EXPERIMENTAL
Intervention: Vadadustat
Number of subjects: 323

Group type: COMPARATOR
Intervention: Darbepoetin alfa
Number of subjects: 323
Study: 32438401

Group type: COMPARATOR
Intervention: Milk protein (31 g, 26.2 g protein: 2.5 g leucine)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Mycoprotein (70 g, 31.5 g protein: 2.5 g leucine)
Number of subjects: 20
Study: 34137291

Group type: COMPARATOR
Intervention: No antibiotic prophylaxis (no AP)
Number of subjects: 421

Group type: COMPARATOR
Intervention: 2-year antibiotic prophylaxis (2-y AP)
Number of subjects: 421

Group type: COMPARATOR
Intervention: Lifetime antibiotic prophylaxis (lifetime AP)
Number of subjects: 421
Study: 34544205

Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg once daily for 3 months
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo for 3 months
Number of subjects: 74
Study: 35248295

Group type: EXPERIMENTAL
Intervention: 6-minute pegboard and ring test (6PBRT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: arm cycle ergometer test (arm CET)
Number of subjects: 0
Study: 32250279

Group type: EXPERIMENTAL
Intervention: Enrolled patients in the PPI‐ePR system
Number of subjects: 2435

Group type: EXPERIMENTAL
Intervention: Enrolled doctors in the PPI‐ePR system
Number of subjects: 2435

Group type: COMPARATOR
Intervention: Nonenrolled patients
Number of subjects: 2435

Group type: COMPARATOR
Intervention: Nonenrolled doctors
Number of subjects: 2435

Group type: COMPARATOR
Intervention: Patients and doctors surveyed
Number of subjects: 2435

Group type: COMPARATOR
Intervention: PPI‐ePR system use
Number of subjects: 2435
Study: 35981086

Group type: EXPERIMENTAL
Intervention: Koji-family.net 3-day program (KF3 PGM)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Usual services (Control)
Number of subjects: 240
Study: 33567400

Group type: EXPERIMENTAL
Intervention: Cenobamate treatment (100–400 mg/day)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Cenobamate treatment (150–400 mg/day)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Cenobamate treatment
Number of subjects: 49
Study: 33070529

Group type: EXPERIMENTAL
Intervention: H63D gene variant in sporadic ALS group (16 cases, 13%)
Number of subjects: 124

Group type: COMPARATOR
Intervention: H63D gene variant in healthy control group (8 cases, 4%)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Allele level comparison of H63D gene variant
Number of subjects: 124
Study: 34293411

Group type: EXPERIMENTAL
Intervention: Epidural fentanyl 2.5 mcg.mL‐1 (Group 1)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Epidural fentanyl 5 mcg.mL‐1 (Group 2)
Number of subjects: 16
Study: 33058835

Group type: EXPERIMENTAL
Intervention: Testosterone (150 mg)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 139
Study: 36281113

Group type: EXPERIMENTAL
Intervention: Low-to moderate intensity aerobic training (30 minutes daily)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Conventional customized physiotherapy (60 minutes daily)
Number of subjects: 37
Study: 33625653

Group type: EXPERIMENTAL
Intervention: Pharmacist interventions for drug-related problems (DRPs)
Number of subjects: 172
Study: 32487558

Group type: EXPERIMENTAL
Intervention: Recalculated height-adjusted total kidney volume (htTKV) excluding exophytic cysts
Number of subjects: 558

Group type: EXPERIMENTAL
Intervention: Recalculated htTKV
Number of subjects: 558

Group type: COMPARATOR
Intervention: Original htTKV
Number of subjects: 558
Study: 33731646

Group type: EXPERIMENTAL
Intervention: Free ROM Group (unlimited ROM)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Limited ROM Group (restricted to 90 degrees)
Number of subjects: 60
Study: 35098958

Group type: EXPERIMENTAL
Intervention: Formula containing high sn-2 palmitate for 16 weeks
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control formula using regular vegetable oil for 16 weeks
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Breast milk for 16 weeks
Number of subjects: 102
Study: 33726810

Group type: EXPERIMENTAL
Intervention: Hip arthroscopic surgery (HA)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Personalised hip therapy (PHT)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Personalised hip therapy (PHT) to Hip arthroscopic surgery (HA)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both HA and PHT
Number of subjects: 40
Study: 35968501

Group type: EXPERIMENTAL
Intervention: Sufentanil combined with propofol (0.01‐0.03 μg/(kg·min) of sufentanil + 80‐100 μg/(kg·min) of propofol)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Fentanyl (3 μg/(kg·h) of fentanyl + 80‐100 μg/(kg·min) of propofol)
Number of subjects: 120
Study: 34543871

Group type: EXPERIMENTAL
Intervention: Vistusertib (75 mg/m2 BID on 2 days/week)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Vistusertib (30 mg/m2 BID on 3 days/week) combined with temozolomide (100 mg/m2/day) and topotecan (0.50 mg/m2/day)
Number of subjects: 14
Study: 35457366

Group type: EXPERIMENTAL
Intervention: Mindfulness stress management intervention for 12 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 60
Study: 34563187

Group type: EXPERIMENTAL
Intervention: Pimobendan
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 32813780

Group type: EXPERIMENTAL
Intervention: 3D atlas
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Traditional method combined with new technologies
Number of subjects: 62

Group type: COMPARATOR
Intervention: Traditional method
Number of subjects: 62

Group type: COMPARATOR
Intervention: Ultrasound
Number of subjects: 62
Study: 35818342

Group type: EXPERIMENTAL
Intervention: Smartphone-assisted patient-initiated care (app intervention group)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 103
Study: 32771267

Group type: EXPERIMENTAL
Intervention: Training with music (TWM)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Training without music (TWtM)
Number of subjects: 17
Study: 35795140

Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP) and fasting triglyceride glucose (TyG) used to create the CRP-TyG index (CTI).
Number of subjects: 5221
Study: 34548368

Group type: EXPERIMENTAL
Intervention: Clarithromycin 800 mg/day
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Clarithromycin 400 mg/day
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard treatment without clarithromycin
Number of subjects: 60
Study: 35853583

Group type: EXPERIMENTAL
Intervention: Prostaglandin use for induction
Number of subjects: 941

Group type: EXPERIMENTAL
Intervention: Cesarean delivery
Number of subjects: 941
Study: 34551168

Group type: EXPERIMENTAL
Intervention: Custom-made meshes with cross-linked collagen membranes (Mesh+)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Custom-made meshes (Mesh-)
Number of subjects: 30
Study: 33558285

Group type: EXPERIMENTAL
Intervention: Enisamium
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 32335133

Group type: EXPERIMENTAL
Intervention: Telemedicine (myIBDcoach)
Number of subjects: 909

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 909
Study: 34215452

Group type: EXPERIMENTAL
Intervention: MenB‐FHbp booster dose administered 48 months after primary series
Number of subjects: 698

Group type: EXPERIMENTAL
Intervention: MenB‐FHbp primary vaccination
Number of subjects: 698

Group type: EXPERIMENTAL
Intervention: MenB‐FHbp booster dose
Number of subjects: 698

Group type: EXPERIMENTAL
Intervention: MenB‐FHbp vaccination
Number of subjects: 698
Study: 32379374

Group type: EXPERIMENTAL
Intervention: Microneedling followed by TCA 70%
Number of subjects: 32

Group type: COMPARATOR
Intervention: Intraderma injection of 5-fluorouracil (5-FU)
Number of subjects: 32
Study: 32713183

Group type: EXPERIMENTAL
Intervention: Prednisolone, 0.5 mg/kg (maximum dose 20 mg/day) qAM × 3 days postoperatively
Number of subjects: 1358

Group type: COMPARATOR
Intervention: Non-steroid group
Number of subjects: 1358
Study: 33459540

Group type: EXPERIMENTAL
Intervention: Modified-release betahistine (48 mg once daily)
Number of subjects: 264

Group type: COMPARATOR
Intervention: Betaserc (24 mg twice daily)
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 264
Study: 32473901

Group type: EXPERIMENTAL
Intervention: Intravitreal Aflibercept
Number of subjects: 55
Study: 35869533

Group type: EXPERIMENTAL
Intervention: Empower-Autism programme plus treatment-as-usual
Number of subjects: 380

Group type: COMPARATOR
Intervention: Usual local post-diagnostic offer plus treatment-as-usual
Number of subjects: 380
Study: 33434444

Group type: EXPERIMENTAL
Intervention: Nintendo Wii‐Sports Boxing (Boxing)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Nintendo Wii Lego Star Wars (Lego)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Resting
Number of subjects: 28
Study: 35833285

Group type: EXPERIMENTAL
Intervention: Rapilin
Number of subjects: 590

Group type: COMPARATOR
Intervention: NovoRapid
Number of subjects: 590
Study: 33966415

Group type: EXPERIMENTAL
Intervention: Hospital-community integrated service model (HCISM) intervention
Number of subjects: 120

Group type: COMPARATOR
Intervention: Routine intervention (Control group)
Number of subjects: 120
Study: 33150681

Group type: EXPERIMENTAL
Intervention: Low-sodium, home-delivered meals
Number of subjects: 20
Study: 33266039

Group type: EXPERIMENTAL
Intervention: Telephone-based parent intervention (4 weekly 30-min support calls)
Number of subjects: 394

Group type: EXPERIMENTAL
Intervention: Telephone-based parent intervention
Number of subjects: 394

Group type: COMPARATOR
Intervention: Control (printed materials)
Number of subjects: 394
Study: 34311098

Group type: EXPERIMENTAL
Intervention: Progressive Resistance Training (PRT) intervention consisting of 24 supervised exercise sessions over 12 weeks
Number of subjects: 90

Group type: COMPARATOR
Intervention: Exercise educational materials (Control)
Number of subjects: 90
Study: 36105267

Group type: EXPERIMENTAL
Intervention: START Together (experimental treatment)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Treatment as usual (control)
Number of subjects: 20
Study: 32404775

Group type: EXPERIMENTAL
Intervention: AD providers
Number of subjects: 113

Group type: COMPARATOR
Intervention: non-AD providers
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: AD providers (baseline)
Number of subjects: 113
Study: 35019078

Group type: EXPERIMENTAL
Intervention: 7 J photobiomodulation (G7)
Number of subjects: 40

Group type: COMPARATOR
Intervention: 1 J photobiomodulation (G1)
Number of subjects: 40

Group type: COMPARATOR
Intervention: 4 J photobiomodulation (G4)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 40
Study: 34537477

Group type: EXPERIMENTAL
Intervention: Meditation app
Number of subjects: 239

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 239
Study: 32647985

Group type: EXPERIMENTAL
Intervention: Stapled anopexy (SA) with stapled line height (SLH) of 4.5 cm (group A)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Stapled anopexy (SA) with stapled line height (SLH) of 6 cm (group B)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Stapled anopexy (SA) with SLH of 4.5 cm (group A)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Stapled anopexy (SA) with SLH of 6 cm (group B)
Number of subjects: 119
Study: 35109482

Group type: EXPERIMENTAL
Intervention: Our Family Journey (OFJ) program; culturally tailored, evidence-based skill-building program delivered over 4 weeks.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Written dementia caregiving information (control condition).
Number of subjects: 60
Study: 34688369

Group type: EXPERIMENTAL
Intervention: Mirtazapine (titrated to 45 mg)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Mirtazapine
Number of subjects: 204
Study: 36448932

Group type: EXPERIMENTAL
Intervention: Insulclock (active group)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Masked group (control)
Number of subjects: 55
Study: 33191484

Group type: EXPERIMENTAL
Intervention: Prognostic nomogram based on competing-risk regression model for predicting cancer-specific death (CSD).
Number of subjects: 1535

Group type: EXPERIMENTAL
Intervention: Risk classification system based on total nomogram scores.
Number of subjects: 1535
Study: 32057131

Group type: EXPERIMENTAL
Intervention: Functional Imagery Training (FIT)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 38
Study: 36299765

Group type: EXPERIMENTAL
Intervention: 6-month lay health worker intervention including training, support, targeted care plan, case management, and financial subsidy
Number of subjects: 222

Group type: COMPARATOR
Intervention: Usual care and health information on diabetes risk management
Number of subjects: 222
Study: 33875799

Group type: EXPERIMENTAL
Intervention: 2.5 g/d of omega-3
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: 1.25 g/d of omega-3
Number of subjects: 138

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138
Study: 34772616

Group type: EXPERIMENTAL
Intervention: Isometric neck strengthening exercises (3 times per week for 12 weeks)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard strength and conditioning program (control group)
Number of subjects: 40
Study: 34880028

Group type: EXPERIMENTAL
Intervention: 3-month follow-up group (CT scan every 3 months)
Number of subjects: 886

Group type: COMPARATOR
Intervention: 6-month follow-up group (CT scan every 6 months)
Number of subjects: 886

Group type: EXPERIMENTAL
Intervention: 3-month follow-up group
Number of subjects: 886

Group type: COMPARATOR
Intervention: 6-month follow-up group
Number of subjects: 886
Study: 33211881

Group type: EXPERIMENTAL
Intervention: Mothers with more egalitarian gender norm attitudes
Number of subjects: 4667

Group type: EXPERIMENTAL
Intervention: Mothers in households receiving extra modules on sanitation and hygiene
Number of subjects: 4667

Group type: EXPERIMENTAL
Intervention: Mothers experiencing time stress
Number of subjects: 4667

Group type: EXPERIMENTAL
Intervention: Mothers with greater social support
Number of subjects: 4667

Group type: EXPERIMENTAL
Intervention: Mothers receiving extra complementary feeding modules
Number of subjects: 4667

Group type: EXPERIMENTAL
Intervention: Depressed mothers
Number of subjects: 4667
Study: 32667654

Group type: EXPERIMENTAL
Intervention: Rotigotine 2 mg transdermal patch for 1 week followed by a 4 mg patch for 23 weeks
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo transdermal patch for 24 weeks
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Rotigotine
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study: 34073163

Group type: EXPERIMENTAL
Intervention: Resveratrol (RSV) supplementation for 30 days
Number of subjects: 48

Group type: COMPARATOR
Intervention: Energy restriction (ER) for 30 days
Number of subjects: 48
Study: 33371905

Group type: EXPERIMENTAL
Intervention: High-dose cholecalciferol (two 200,000 IU drinking vials at once on the day of inclusion)
Number of subjects: 260

Group type: COMPARATOR
Intervention: Standard-dose cholecalciferol (one 50,000 IU drinking vial on the day of inclusion)
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: High-dose cholecalciferol
Number of subjects: 260

Group type: COMPARATOR
Intervention: Standard-dose cholecalciferol
Number of subjects: 260
Study: 34952709

Group type: EXPERIMENTAL
Intervention: Palm Stimulator
Number of subjects: 159

Group type: COMPARATOR
Intervention: ShotBlocker
Number of subjects: 159

Group type: COMPARATOR
Intervention: Control
Number of subjects: 159
Study: 34160600

Group type: EXPERIMENTAL
Intervention: TYRX™ absorbable antibacterial envelope
Number of subjects: 0
Study: 32437703

Group type: EXPERIMENTAL
Intervention: Graphic warning without efficacy information
Number of subjects: 1352

Group type: EXPERIMENTAL
Intervention: Graphic warning with efficacy information
Number of subjects: 1352

Group type: COMPARATOR
Intervention: Text-only warning without efficacy information
Number of subjects: 1352

Group type: COMPARATOR
Intervention: Text-only warning with efficacy information
Number of subjects: 1352
Study: 35996195

Group type: EXPERIMENTAL
Intervention: Surgery plus endovascular MMA embolization
Number of subjects: 154

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 154
Study: 33515175

Group type: EXPERIMENTAL
Intervention: Gambling activities (17 types)
Number of subjects: 799

Group type: EXPERIMENTAL
Intervention: Pathologic gambling
Number of subjects: 799

Group type: EXPERIMENTAL
Intervention: Risk factors for PPG
Number of subjects: 799

Group type: EXPERIMENTAL
Intervention: Acculturation
Number of subjects: 799
Study: 32339296

Group type: EXPERIMENTAL
Intervention: Noncash incentives for blood donation
Number of subjects: 2229
Study: 34954857

Group type: EXPERIMENTAL
Intervention: Zoledronic acid (ZOL) 5 mg iv with vitamin D 1000 IU/d
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo with vitamin D 1000 IU/d
Number of subjects: 48
Study: 33831216

Group type: EXPERIMENTAL
Intervention: Non-intubated thoracic surgery
Number of subjects: 40

Group type: COMPARATOR
Intervention: Intubated thoracic surgery
Number of subjects: 40
Study: 34003735

Group type: EXPERIMENTAL
Intervention: Box simulator (with artificial nodules)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Fruit (banana)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Both groups after using their assigned simulator
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Both groups evaluated through OSCE
Number of subjects: 51
Study: 33852722

Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 37
Study: 34181084

Group type: EXPERIMENTAL
Intervention: Scalp nerve blockade (B) and wound infiltration (I) with 0.25% bupivacaine, 1% lidocaine, and 1:200,000 epinephrine
Number of subjects: 141

Group type: COMPARATOR
Intervention: Systemic analgesia (S) with 1 gram of paracetamol and 2 mg/kg ketoprofen administered IV after skin closure
Number of subjects: 141
Study: 35803709

Group type: EXPERIMENTAL
Intervention: Tablet-based intervention
Number of subjects: 220
Study: 33486139

Group type: EXPERIMENTAL
Intervention: Apomorphine infusion (APO)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study: 616775801

Group type: EXPERIMENTAL
Intervention: GDF-15 group 1 (<1,200 ng/L)
Number of subjects: 8474

Group type: EXPERIMENTAL
Intervention: GDF-15 group 3 (>1,800 ng/L)
Number of subjects: 8474

Group type: EXPERIMENTAL
Intervention: GDF-15 levels
Number of subjects: 8474

Group type: EXPERIMENTAL
Intervention: GDF-15
Number of subjects: 8474
Study: 34431989

Group type: EXPERIMENTAL
Intervention: Antibacterial envelope
Number of subjects: 1943

Group type: COMPARATOR
Intervention: No antibacterial envelope
Number of subjects: 1943